Eton Pharmaceuticals, Inc. ETON Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $24.27M+40.4% | $21.28M+82.7% | $22.46M+118% | $18.93M+109% | $17.28M+117% | ||
| $9.53M+28.4% | $8.18M+58.2% | $14.6M+263% | $7M+103% | $7.42M+151% | ||
| $14.74M+49.4% | $13.1M+102% | $7.86M+24.6% | $11.92M+112% | $9.86M+96.9% | ||
| 60.7%+3.7pp | 61.6%+6.0pp | 35%-26.1pp | 63%+1.0pp | 57.1%-5.8pp | ||
| $1.88M+61.5% | $1.78M— | $1.11M+120% | $3.71M+25.0% | $1.16M+78.3% | ||
| $10.45M+13.9% | $8.86M+31.8% | $8.11M+53.3% | $9.69M+73.3% | $9.17M+77.9% | ||
| $12.32M+19.3% | $10.64M+81.9% | $9.22M+59.1% | $13.4M+56.5% | $10.33M+77.9% | ||
| $12.32M+19.3% | $10.64M+81.9% | $9.22M+59.1% | $13.4M+56.5% | $10.33M+77.9% | ||
| $2.41M+614% | —— | -$1.36M-368% | -$1.48M+49.7% | -$470K+41.3% | ||
| 9.9%+12.7pp | —— | -6.1%-11.0pp | -7.8%+24.6pp | -2.7%+7.3pp | ||
| -$840K+18.3% | —— | -$592K-7,300% | -$1.04M-1,908% | -$1.03M-9,245% | ||
| $1.57M+205% | —— | -$1.96M-490% | -$2.52M+15.7% | -$1.5M-84.7% | ||
| $20K-73.0% | —— | -$28K+77.8% | $66K+22.2% | $74K— | ||
| $1.55M+199% | —— | -$1.93M-407% | -$2.59M+15.0% | -$1.57M-93.8% | ||
| 6.4%+15.5pp | —— | -8.6%-14.7pp | -13.7%+19.9pp | -9.1%+1.1pp | ||
| $0.05+183% | —— | -$0.07-450% | —— | -$0.06-100% | ||
| $0.06+200% | —— | -$0.07-450% | -$0.10+16.7% | -$0.06-100% | ||
| 31.5M+17.3% | —— | 26.9M+1.3% | —— | 26.9M+4.4% | ||
| 27.3M+1.5% | 26.9M+3.9% | 26.9M+3.8% | 26.9M+4.3% | 26.9M+4.4% | ||
| -$840K+18.3% | —— | -$592K-7,300% | -$1.04M-1,908% | -$1.03M-9,245% | ||
| $24.27M+40.4% | $21.28M+82.7% | $22.46M+118% | $18.93M+109% | $17.28M+117% | ||
| $2.41M+614% | —— | -$1.36M-368% | -$1.48M+49.7% | -$470K+41.3% | ||
| $3.55M+553% | —— | -$354K-145% | -$470K+82.3% | $543K+196% | ||
| $3.55M+553% | —— | -$354K-145% | -$470K+82.3% | $543K+196% | ||
| 14.6%+11.5pp | —— | -1.6%-9.2pp | -2.5%+26.8pp | 3.1%+10.2pp | ||
| $2.41M+614% | —— | -$1.36M-368% | -$1.48M+49.7% | -$470K+41.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Eton Pharmaceuticals, Inc.'s revenue?
- Eton Pharmaceuticals, Inc. (ETON) generated $86.9M in revenue over the trailing twelve months, up 79.9% year over year.
- Is Eton Pharmaceuticals, Inc. profitable?
- Eton Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $4.5M over the trailing twelve months, a -9.5% net margin.
- What are Eton Pharmaceuticals, Inc.'s profit margins?
- Gross margin is 54.8% and operating margin is -15.1%, with a -9.5% net margin.
- What is Eton Pharmaceuticals, Inc.'s earnings per share?
- Eton Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-0.06.
- Where does Eton Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Eton Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
